Literature DB >> 34611720

Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.

Kelsey Uminski1, Roy Khalife2, Jill Fulcher2, Lisa Duffett2, Tzu-Fei Wang2, Alan Tinmouth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34611720     DOI： 10.1007/s00277-021-04688-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Decreased activity of clotting factor V during ALL consolidation treatment with mercaptopurine in a child.

Authors:  Claire Vignand; Gérard Couillault; Genevieve Jolimoy; Fabienne Dutrillaux; Catherine Sgro
Journal:  Ann Pharmacother       Date:  2006-09-05       Impact factor: 3.154

2.  Decrease in factor V activity: a new adverse effect of purine analogs in inflammatory bowel diseases?

Authors:  S Poupeney; X Dray; S Reignier; K Vahedi; M Alhenc; S Belluci; P Marteau
Journal:  Inflamm Bowel Dis       Date:  2008-07       Impact factor: 5.325

3.  Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology.

Authors:  Andrew D Mumford; Sam Ackroyd; Raza Alikhan; Louise Bowles; Pratima Chowdary; John Grainger; Jason Mainwaring; Mary Mathias; Niamh O'Connell
Journal:  Br J Haematol       Date:  2014-08-06       Impact factor: 6.998

4.  Isolated decrease in factor V in children treated by 6-Mercaptopurine for acute lymphoblastic Leukemia.

Authors:  B Filhon; C Dumesnil; P Van Dreden; P Schneider; M Vasse; J P Vannier
Journal:  Thromb Res       Date:  2014-08-29       Impact factor: 3.944

5.  The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

Authors:  R A White; P Workman; J M Brown
Journal:  Radiat Res       Date:  1980-12       Impact factor: 2.841

6.  Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders.

Authors:  F Peyvandi; R Palla; M Menegatti; S M Siboni; S Halimeh; B Faeser; H Pergantou; H Platokouki; P Giangrande; K Peerlinck; T Celkan; N Ozdemir; C Bidlingmaier; J Ingerslev; M Giansily-Blaizot; J F Schved; R Gilmore; A Gadisseur; M Benedik-Dolničar; L Kitanovski; D Mikovic; K M Musallam; F R Rosendaal
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

7.  THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.

Authors:  Jeanette Greiner; Martin Schrappe; Alexander Claviez; Martin Zimmermann; Charlotte Niemeyer; Reinhard Kolb; Wolfgang Eberl; Frank Berthold; Eva Bergsträsser; Astrid Gnekow; Elisabeth Lassay; Peter Vorwerk; Melchior Lauten; Axel Sauerbrey; Johannes Rischewski; Andreas Beilken; Günter Henze; Wolfgang Korte; Anja Möricke
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.